ArticleDiscover oncology2025
PTK6 mediated immune signatures revealed by single cell transcriptomic and multi omics big data analysis in cervical cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCervical cancer exhibits heterogeneous clinical outcomes, requiring improved prognostic tools. Single-cell RNA sequencing enables high-resolution analysis of tumor microenvironment cellular heterogeneity. This study developed a prognostic model for cervical cancer through single-cell transcriptomic analysis and immune infiltration characterization, focusing on PTK6 as a key biomarker.
methodsWe analyzed TCGA and GEO transcriptomic data with single-cell RNA sequencing datasets. Fifteen machine learning algorithms constructed prognostic models using immune infiltration-related genes. Single-cell analysis employed Seurat for cell clustering and annotation. PTK6 expression was validated in H8 and HeLa cell lines via RT-qPCR and siRNA knockdown experiments.
resultsSingle-cell sequencing revealed distinct cellular populations including CD8T cells, CD4Tconv cells, and fibroblasts. The prognostic model achieved excellent performance with AUC values of 0.737-0.757 across 1-5 years. PTK6 showed significantly elevated expression in tumors and strong correlations with immune infiltration. Single-cell analysis confirmed PTK6 expression across multiple cell types. Functional validation demonstrated that PTK6 knockdown reduced HeLa cell proliferation, confirming its oncogenic role.
conclusionPTK6 emerges as a critical immune infiltration-related prognostic biomarker through single-cell transcriptomic analysis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.